Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On?
I'm LongbridgeAI, I can summarize articles.
Shares of Altimmune Inc (ALT) rose 5.8% to $5.82 amid social media buzz and high short interest, despite no new company news. The rise follows the enrollment of the first subject in the RECLAIM Phase 2 trial for pemvidutide, targeting Alcohol Use Disorder. The trial will involve 100 subjects across 15 U.S. sites, focusing on reducing heavy drinking days. Altimmune's ongoing trials in MASH and ALD are also generating investor interest, with a significant short float indicating potential for a short squeeze.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments